En Carta Diagnostics is a synthetic-biology biotech company leveraging patented technologies to decentralise highly reliable molecular diagnostic solutions.
En Carta Diagnostics has raised €6.5M across 2 funding rounds from 7 investors, most recently a round in Jul 2026. Based in Paris, France; active in Healthtech. Data as of 7 Aug 2026.
Timing: too soon vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
| Date |
|---|
| Stage |
|---|
| Amount |
|---|
| Investors |
|---|
| 2026-07-10 | Other | €5.0M | 50 Partners Health,Blue Forest Ventures,Bpifrance,Business Angels,CentraleSupélec Venture,other partners+1 more | View deal → |
| 2024-05-23 | Other | €1.5M | Business Angels,CentraleSupélec Venture | View deal → |
